Clinical Trial

Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 10, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-22; most recent amendment 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT06998628
Lead Sponsor Tanta University
Collaborators: Dr. Mustafa Adel Mustafa Elmenawy Lecturer of Rheumatology and Rehabilitation, Faculty of Medicine - El-Azhar University - Damietta
Conditions Rheumatoid Arthritis
Enrollment 50 participants
Start Date 2025-06-02
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-10